Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma

Abstract

IL-2, used as a continuous infusion at a dose level of 12 x 10(6) IU/m2/day, 4 times every week for 4 weeks, has activity against metastatic melanoma similar to that reported with high dose IL-2 given in a bolus schedule.